ES2743788T3 - Compuestos heterobicíclicos y su uso para el tratamiento de tuberculosis - Google Patents

Compuestos heterobicíclicos y su uso para el tratamiento de tuberculosis Download PDF

Info

Publication number
ES2743788T3
ES2743788T3 ES15763096T ES15763096T ES2743788T3 ES 2743788 T3 ES2743788 T3 ES 2743788T3 ES 15763096 T ES15763096 T ES 15763096T ES 15763096 T ES15763096 T ES 15763096T ES 2743788 T3 ES2743788 T3 ES 2743788T3
Authority
ES
Spain
Prior art keywords
fluoro
dihydroquinolin
methoxy
compound
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES15763096T
Other languages
English (en)
Spanish (es)
Inventor
Hiroshi Shimizu
Yoshikazu Kawano
Shunpei Ishikawa
Yukitaka Uematsu
Toshio Shinohara
Motohiro Itotani
Yoshikazu Haraguchi
Isao Takemura
Atsunori Kaneshige
Yuya Nakai
Norimitsu Hariguchi
Yohei Hayashi
Makoto Matsumoto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Co Ltd
Original Assignee
Otsuka Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54105947&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2743788(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharmaceutical Co Ltd filed Critical Otsuka Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2743788T3 publication Critical patent/ES2743788T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
ES15763096T 2014-08-28 2015-08-28 Compuestos heterobicíclicos y su uso para el tratamiento de tuberculosis Active ES2743788T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014174528 2014-08-28
PCT/JP2015/004371 WO2016031255A1 (en) 2014-08-28 2015-08-28 Heterobicyclic compounds and their use for the treatment of tuberculosis

Publications (1)

Publication Number Publication Date
ES2743788T3 true ES2743788T3 (es) 2020-02-20

Family

ID=54105947

Family Applications (1)

Application Number Title Priority Date Filing Date
ES15763096T Active ES2743788T3 (es) 2014-08-28 2015-08-28 Compuestos heterobicíclicos y su uso para el tratamiento de tuberculosis

Country Status (29)

Country Link
US (2) US10053446B2 (OSRAM)
EP (1) EP3186240B9 (OSRAM)
JP (1) JP6625612B2 (OSRAM)
KR (1) KR102418413B1 (OSRAM)
CN (1) CN106795117B (OSRAM)
AP (1) AP2017009788A0 (OSRAM)
AR (1) AR101704A1 (OSRAM)
AU (1) AU2015307873B2 (OSRAM)
BR (1) BR112017003231B1 (OSRAM)
CA (1) CA2959478C (OSRAM)
CY (1) CY1122286T1 (OSRAM)
DK (1) DK3186240T3 (OSRAM)
EA (1) EA038414B1 (OSRAM)
ES (1) ES2743788T3 (OSRAM)
HR (1) HRP20191486T2 (OSRAM)
HU (1) HUE045025T2 (OSRAM)
IL (1) IL250484B (OSRAM)
LT (1) LT3186240T (OSRAM)
MX (1) MX2017002312A (OSRAM)
MY (1) MY189098A (OSRAM)
NZ (1) NZ729064A (OSRAM)
PH (1) PH12017500290B1 (OSRAM)
PL (1) PL3186240T3 (OSRAM)
PT (1) PT3186240T (OSRAM)
SG (1) SG11201700882XA (OSRAM)
SI (1) SI3186240T1 (OSRAM)
TW (1) TWI687409B (OSRAM)
WO (1) WO2016031255A1 (OSRAM)
ZA (1) ZA201700916B (OSRAM)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR101704A1 (es) * 2014-08-28 2017-01-04 Otsuka Pharma Co Ltd Compuestos heterocíclicos fusionados
WO2017146246A1 (ja) * 2016-02-26 2017-08-31 大塚製薬株式会社 ピペリジン誘導体
US20210292333A1 (en) 2018-06-15 2021-09-23 Cadila Healthcare Limited Condensed azaheteroaryl compounds having antibacterial activity against tuberculosis bacteria
JP2023085582A (ja) * 2020-05-11 2023-06-21 大塚製薬株式会社 ジヒドロキノリノン化合物の共結晶
EP4201407A4 (en) * 2020-08-19 2024-07-31 MitoImmune Therapeutics Inc. ANTIOXIDANT TARGETING MITOCHONDRIA AS AN AGENT FOR THE TREATMENT OF PATHOLOGICAL INFLAMMATION CAUSED BY MABC-R INFECTION
CN116102537B (zh) * 2021-11-10 2024-10-01 四川大学 一种喹啉酮类衍生物及其制备方法和用途
CN116589448B (zh) * 2023-04-24 2025-10-28 西南交通大学 一种3,4-二氢喹啉酮衍生物及其应用
WO2025183016A1 (ja) * 2024-02-26 2025-09-04 大塚製薬株式会社 Ｑｕａｂｏｄｅｐｉｓｔａｔ含有組成物
WO2025183017A1 (ja) * 2024-02-26 2025-09-04 大塚製薬株式会社 Ｑｕａｂｏｄｅｐｉｓｔａｔ含有組成物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2608788B2 (ja) * 1988-10-31 1997-05-14 大塚製薬 株式会社 精神分裂病治療剤
US5668127A (en) 1995-06-26 1997-09-16 Pathogenesis Corporation Nitroimidazole antibacterial compounds and methods of use thereof
TWI347946B (en) 2002-10-11 2011-09-01 Otsuka Pharma Co Ltd 2,3-dihydro-6-nitroimidazo[2,1-b]oxazole compound
GB0319150D0 (en) * 2003-08-14 2003-09-17 Glaxo Group Ltd Novel compounds
ZA200602184B (en) * 2003-10-31 2007-10-31 Otsuka Pharma Co Ltd 2,3-dihydro-6-nitroimidazo (2,1-B) oxazole compounds for the treatment of tuberculosis
WO2005042542A1 (en) 2003-10-31 2005-05-12 Otsuka Pharmaceutical Co., Ltd. 2,3-dihydro-6-nitroimidazo (2,1-b) oxazole compounds for the treatment of tuberculosis
JP4761756B2 (ja) 2003-10-31 2011-08-31 大塚製薬株式会社 ２，３−ジヒドロイミダゾ［２，１−ｂ］オキサゾ−ル化合物
CN101891680B (zh) * 2004-06-24 2014-10-29 沃泰克斯药物股份有限公司 Atp-结合弹夹转运蛋白的调控剂
WO2007099828A1 (ja) 2006-02-23 2007-09-07 Shionogi & Co., Ltd. 環式基で置換された含窒素複素環誘導体
GB0812648D0 (en) 2008-07-10 2008-08-20 Prosidion Ltd Compounds
WO2010045987A1 (en) * 2008-10-23 2010-04-29 Glaxo Group Limited Substituted (aza) -1-methyl-1h-quin0lin-2-0nes as antibacterials
EP2459570B1 (en) 2009-07-31 2014-12-24 Global Alliance For Tb Drug Development Nitroimidazooxazine analogues and their uses
EP2697232B1 (en) 2011-04-15 2016-05-18 Otsuka Pharmaceutical Co., Ltd. 6,7-dihydroimidazo[2,1-b][1,3]oxazine bactericides
AR101704A1 (es) * 2014-08-28 2017-01-04 Otsuka Pharma Co Ltd Compuestos heterocíclicos fusionados
WO2017146246A1 (ja) * 2016-02-26 2017-08-31 大塚製薬株式会社 ピペリジン誘導体

Also Published As

Publication number Publication date
AU2015307873A1 (en) 2017-03-09
MX2017002312A (es) 2017-05-08
AR101704A1 (es) 2017-01-04
LT3186240T (lt) 2019-09-10
US20180312488A1 (en) 2018-11-01
DK3186240T3 (da) 2019-08-26
TW201609658A (zh) 2016-03-16
HRP20191486T1 (hr) 2019-11-15
MY189098A (en) 2022-01-25
HUE045025T2 (hu) 2019-12-30
EP3186240B1 (en) 2019-06-12
ZA201700916B (en) 2019-06-26
BR112017003231A2 (pt) 2017-11-28
AP2017009788A0 (en) 2017-02-28
JP6625612B2 (ja) 2019-12-25
CA2959478C (en) 2023-09-26
BR112017003231B1 (pt) 2022-10-11
SI3186240T1 (sl) 2019-10-30
KR102418413B1 (ko) 2022-07-06
PL3186240T3 (pl) 2020-03-31
KR20170043644A (ko) 2017-04-21
PH12017500290B1 (en) 2023-07-19
IL250484B (en) 2020-04-30
US10464926B2 (en) 2019-11-05
PT3186240T (pt) 2019-09-06
WO2016031255A1 (en) 2016-03-03
EP3186240B9 (en) 2019-12-04
PH12017500290A1 (en) 2017-06-28
AU2015307873B2 (en) 2020-01-16
NZ729064A (en) 2022-09-30
CN106795117B (zh) 2020-06-26
EA201790464A1 (ru) 2017-06-30
EP3186240A1 (en) 2017-07-05
TWI687409B (zh) 2020-03-11
JP2017525697A (ja) 2017-09-07
CA2959478A1 (en) 2016-03-03
CY1122286T1 (el) 2021-01-27
US20170253576A1 (en) 2017-09-07
HRP20191486T2 (hr) 2021-09-17
IL250484A0 (en) 2017-03-30
CN106795117A (zh) 2017-05-31
SG11201700882XA (en) 2017-03-30
US10053446B2 (en) 2018-08-21
EA038414B1 (ru) 2021-08-25

Similar Documents

Publication Publication Date Title
US10464926B2 (en) Heterobicyclic compounds and their use for the treatment of tuberculosis
TWI894229B (zh) 作為yap/taz-tead蛋白-蛋白相互作用抑制劑之聯芳基衍生物
EP3256463B1 (en) 1-(het)arylsulfonyl-(pyrrolidine or piperidine)-2-carboxamide derivatives and their use as trpa1 antagonists
AU2018333913B2 (en) Compound having cyclic structure
TWI873165B (zh) (雜)芳基-甲基-硫代-β-D-吡喃半乳糖苷衍生物
UA121467C2 (uk) Біциклічні анельовані гетероарильні або арильні сполуки та їх застосування як інгібіторів irak4
EP4021904B1 (en) Alpha-d-galactopyranoside derivatives
US20220289732A1 (en) Heterocyclic wdr5 inhibitors as anti-cancer compounds
JP6892858B2 (ja) 第ＸＩａ因子阻害剤
EP4225752B1 (en) Spiro derivatives of alpha-d-galactopyranosides
EP3774739B1 (en) Fused cyclic urea derivatives as crhr2 antagonist
CA3093877A1 (en) Antimalarial hexahydropyrimidine analogues
US20230203007A1 (en) Pyridinylacetamide derivatives as sodium channel activators
JP6976691B2 (ja) 医薬組成物
OA18228A (en) Heterobicyclic compounds and their use for the treatment of tuberculosis.
HK1239683A1 (en) Heterobicyclic compounds and their use for the treatment of tuberculosis
HK1239683B (en) Heterobicyclic compounds and their use for the treatment of tuberculosis
US20250326773A1 (en) Mrgprx2 antagonists, pharmaceutical composition including mrgprx2 antagonist, and method of treating mrgprx2-mediated disease or disorder
TW202321257A (zh) 可用於治療正黏液病毒感染之經取代之吡啶酮化合物
EA047452B1 (ru) Биарильные производные в качестве ингибиторов белок-белкового взаимодействия yap/taz-tead